Identitet

5-Hydroxy Imidacloprid Impurity

Inte angivet · C9H10ClN5O3

01Identitet

Lazychem IDLC-43035
CAS RNInte angivet
PubChem CID19417551
Molecular formulaC9H10ClN5O3
Molecular weight271.66 g/mol
IUPAC nameN-[1-[(6-chloro-3-pyridinyl)methyl]-5-hydroxy-4,5-dihydroimidazol-2-yl]nitramide
InChIKeyMATMQDMQFSFQHB-UHFFFAOYSA-N

02Struktur och stereokemi

Two-dimensional chemical structure of 5-Hydroxy Imidacloprid Impurity
Two-dimensional structure for the PubChem identity linked to this record. Confirm the identifiers before analytical use.

The parsed structure contains 2 rings, includes aromatic atoms, includes aliphatic carbon, contains at least one halogen atom, contains an N-nitroso substructure, contains a nitro substructure. These statements are calculated from the published structure string.

Defined stereocentres0
Ring count2
Secondary amines1
Tertiary amines1
SMILESC1C(N(C(=N1)N[N+](=O)[O-])CC2=CN=C(C=C2)Cl)O
InChIInte angivet

03Stereochemistry

The published structure contains 0 defined and 1 unassigned tetrahedral stereocentre. The exact wedge and dash depiction is shown above.

Defined centres0Structure assigned
Unassigned centres1Structure unspecified
Assignment statusUnassignedExact published identity
Tetrahedral upper bound≤ 2Before symmetry reduction

Published same-connectivity configurations

1 record

These records have the same connectivity, molecular formula and protonation layer, but a different complete InChIKey stereochemical layer. Only separately structure-linked records are shown.

No additional structure-linked configuration with the same connectivity is currently present in the LazyChem dataset.

Scope: The mathematical 2^n value is only an upper bound. Symmetry and other stereogenic elements can change the number of distinct stereoisomers. A hypothetical configuration is not published as a compound record without a verified structure identity.

04Status i Indien

Exact-compound status is evaluated only against the published name and CAS number. Confirm the current official instrument before a regulatory decision.

05Namn och relationer

API och moderläkemedel

Inte angivet

Namn och relationer

    06Källor